The Hidden Price Tag of Myasthenia Gravis: New Review Tallies the True Cost of a Rare Autoimmune Disease

Myasthenia gravis has long been described as a rare disease that most people have never heard of, yet a sweeping new systematic review reveals that its economic footprint is anything but small. The review, published in the Journal of Neurology by Nils Erik Gilhus of the University of Bergen and Haukeland University Hospital together with Selma Conradi Melsom and Christoffer Bugge of Oslo Economics, sifted through 1,374 research records and distilled 44 original studies into the most comprehensive picture to date of what this chronic autoimmune disorder actually costs patients, health systems, and society. The headline finding is stark: even before the arrival of a new generation of ultra-expensive therapies, the total societal cost of myasthenia gravis runs into thousands of euros per patient every year, and the least visible components of that bill may be the largest of all.

The disease itself is a malfunction of the neuromuscular junction, the microscopic relay where nerves hand signals to muscles. In myasthenia gravis, IgG antibodies attack proteins on the postsynaptic muscle membrane, most commonly the acetylcholine receptor, and in other patients the muscle-specific kinase MuSK or lipoprotein receptor-related protein 4, known as LRP4. The result is skeletal muscle weakness that fluctuates with use, classically producing drooping eyelids and double vision, but in generalized cases extending to limb, swallowing, and breathing muscles. Roughly 10 percent of cases are paraneoplastic, driven by a thymoma, and autoimmune comorbidity plus heightened vulnerability to infections add further layers of medical complexity. The hallmark worsening of weakness after repetitive exertion, together with the constant anticipation of an exacerbation, contributes a psychological burden that patients consistently rank among the most disabling features of the condition.

Estimating the cost of such a disease is a formidable methodological challenge, and the review is candid about why. Direct costs, meaning hospital care, outpatient visits, drug treatment, and travel related to diagnosis and management, are relatively straightforward to measure from registries and insurance claims. Indirect costs, including lost productivity, welfare payments, patient time spent in medical care, and reduced earnings, require assumptions that vary widely between studies. Intangible costs, the monetary value of lost life-years and diminished quality of life, are rarely calculated at all, even though validated algorithms exist to convert mortality and quality-of-life data into economic terms. Because disease severity ranges from purely ocular symptoms to life-threatening myasthenic crisis, averages conceal enormous individual variation, and because healthcare systems differ so much between countries, the authors deliberately synthesized findings narratively rather than forcing them into a single meta-analysis.

The numbers that emerge are strikingly consistent in their order of magnitude. In the Nordic countries, direct healthcare costs were estimated at roughly €3,500 to €12,000 per patient per year, with similar figures across other European nations and substantially higher values in the United States. Norwegian registry data for 2020 put direct costs at €3,592 per patient, of which hospital care accounted for 87 percent, while prescription drugs added €335. Neighboring countries with comparable health systems reported higher totals: €12,185 in Denmark, €9,036 in Finland, and €5,997 in Sweden, differences the authors attribute partly to methodological choices about what counts as a direct cost. In Norway, direct costs represented only 15 percent of total societal costs, whereas in the other Nordic studies they made up 55 to 70 percent, a discrepancy that illustrates how sensitive these estimates are to accounting frameworks.

Timing matters as much as geography. Across nearly every dataset, costs spike in the first year after diagnosis, when patients typically undergo hospitalization, diagnostic workup, sometimes thymectomy, and aggressive initial therapy with intravenous immunoglobulin or plasma exchange. A Swedish nationwide registry study found healthcare utilization costs were €7,302 higher in the first year after diagnosis than the year before, with 84 percent of that increase directly attributable to the disease, and costs falling markedly in the second year. Italian data showed mean direct costs of €3,771 in year one, €2,827 in year two, and just €255 in year three. German claims data revealed a dramatic treatment gradient, with average inpatient costs of €2,980 for patients on standard therapy but €38,669 for those needing intensified treatment. Refractory disease multiplies the burden: in England, the 5.6 percent of patients classified as treatment-refractory used at least twice the hospitalizations and outpatient visits of non-refractory patients.

The United States sets the global ceiling. A recent analysis of commercially insured patients between 2017 and 2023 found mean annual total healthcare costs of $65,000 for generalized myasthenia gravis, compared with $15,600 for matched controls, with inpatient care the largest component. Hospital discharges for the disease rose more than sixfold between 2003 and 2013 while claims per discharge climbed from $48,024 to $98,795. The most extreme figures attach to acute deterioration: total costs during exacerbations reached $17,113 per patient per month, myasthenic crisis cost $18,640 per month, and each crisis episode carried an estimated price of $47,027. By contrast, a Chinese patient survey reported median annual direct costs of $2,219 against a median household income of $8,759, and a small Indian cohort recorded median direct costs of $720, figures that still represent a heavy burden relative to local incomes.

Indirect costs, the review argues, are chronically undercounted despite being enormous. Norwegian data for 2020 estimated total productivity loss at €9.89 million, or €8,666 per patient, comprising 35 percent of societal costs, with an additional €1,199 per patient lost in reduced income taxation and €1,258 in patient time costs. Danish, Finnish, and Swedish registry studies found indirect costs of €5,463, €2,676, and €2,679 respectively, dominated by early retirement in the first two countries and sick leave in the third. The human dimension behind these figures is sobering. In Germany, 42 percent of non-retired patients reported employment restrictions, averaging 67 absence days in the first year after diagnosis, and among 1,660 members of the German Myasthenia Association, 73 percent of those working at symptom onset reported job limitations, with nearly half unable to work. A Danish cohort found 41 percent of patients took nine or more weeks of sickness absence in their first year, against 3 percent of references. Surveys from Australia, Brazil, Japan, Taiwan, and China consistently show reduced employment, income loss, and activity impairment, and a pooled analysis put overall employment among patients at just 50 percent.

Perhaps the most provocative element of the review is its treatment of intangible costs, which the authors estimate may account for half of all societal costs of the disease. Using Norwegian registry data and national valuation guidelines, they calculated that myasthenia-related deaths caused 73.5 lost quality-adjusted life-years in 2020, 89 percent of that loss concentrated in patients over 60. The average annual loss of health-related quality of life attributable to the disease was 0.22 QALYs versus 0.19 in the general population, translating into €8,428 per patient per year for lost life-years and €4,056 for reduced quality of life, a combined intangible cost of €12,484 annually. These losses rest on well-documented epidemiology: Danish data show a matched mortality ratio of 1.8 for patients, with excess mortality across age groups and especially in the first year after diagnosis, while reduced quality of life is confirmed in cohorts worldwide, greater in women, and normalized only in long-term remission.

The review arrives at a pivotal moment. Complement inhibitors such as eculizumab, approved for myasthenia gravis in 2017, and FcRn blockers such as efgartigimod, approved in 2021, carry listed prices of up to $500,000 per year in some countries, and targeted B and T cell therapies including CAR-T constructs and bispecific antibodies are showing promise in early-phase trials. Most published cost studies predate these drugs, meaning current averages likely understate the coming expense curve. Yet the authors argue the calculus can still favor innovation: a minority of patients with frequent hospitalizations and intensive care needs drives most costs, so expensive new treatments aimed at this group may prove cost-effective if they reduce crises, mortality, and productivity loss. The critical caveat is access, since present pricing means most patients worldwide cannot obtain optimal therapy. Precise, updated, country-specific cost data, the review concludes, are not bureaucratic luxuries but the essential foundation for reimbursement decisions, treatment guidelines, and the start-and-stop criteria that will determine which patients benefit from medicine’s newest and most expensive tools.

Subject of Research: Healthcare costs and societal burden of myasthenia gravis

Article Title: Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review

Article References: Gilhus, N. E., Melsom, S. C., & Bugge, C. (2026). Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review. Journal of Neurology, 273(10), Article 648. https://doi.org/10.1007/s00415-026-14111-6

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14111-6

Keywords: myasthenia gravis, healthcare costs, health economics, neuromuscular disease, autoimmune disease, systematic review, direct costs, indirect costs, quality of life, productivity loss, biologics, health policy